| Patient | Gwen Ifill |
|---|---|
| Date of birth | 1965-09-29 |
| Identifiers | MRN HR-ML032-SYN; SSN (made up) 000-32-5814 |
| Document date | 2026-06-30 |
| Author | Lorna Achebe-Price, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
End of combination treatment: CT result, thyroid tests, and the first maintenance dose. [S]
Ms. Ifill returns three weeks after her sixth and last cycle of combination treatment, all given on schedule. The CT a week ago shows no evidence of disease. Over the past month she has felt more tired than after earlier cycles, colder than usual, and a little slowed down, without low mood. The tingling in her toes is unchanged and does not affect walking. She has had no vaginal bleeding, pelvic pain, cough, breathlessness, diarrhea, rash, headache, dizziness or leg swelling. She saw Dr. Delacroix with the CT result and is ready to begin maintenance dostarlimab today. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Treatment | Six cycles of dostarlimab, carboplatin and paclitaxel completed on schedule |
| Response | CT: no evidence of disease |
| New symptoms | Tiredness and feeling cold for a month |
| Neuropathy | Grade 1, unchanged |
| Today | First maintenance dose of dostarlimab 1000 mg |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired and feels cold; no fever or weight loss |
| Genitourinary | Negative | No vaginal bleeding or discharge |
| Gastrointestinal | Negative | No diarrhea, constipation or abdominal pain |
| Respiratory | Negative | No cough or breathlessness |
| Neurological | Positive | Tingling in the toes, unchanged; no headache or dizziness |
| Endocrine | Positive | Cold intolerance; no thirst |
| Psychiatric | Negative | Mood good; PHQ-9 4; no thoughts of self-harm |
7 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a day | Two tablets every 6 hours as needed | Oral route | 2026-02-03 to 2026-02-17 | completed | S |
| Dostarlimab 50 mg/mL injection, 500 mg intravenously over 30 minutes on day 1 of each 21-day cycle, before carboplatin and paclitaxel, for six cycles | Day 1 every 21 days for six cycles | Intravenous route | 2026-02-24 to 2026-06-09 | completed | S |
| Carboplatin 10 mg/mL injection, 575 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cycles | Day 1 every 21 days for six cycles | Intravenous route | 2026-02-24 to 2026-06-09 | completed | S |
| Paclitaxel 6 mg/mL injection, 320 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidine | Day 1 every 21 days for six cycles | Intravenous route | 2026-02-24 to 2026-06-09 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea | One tablet every 8 hours as needed for nausea | Oral route | 2026-02-24 to 2026-06-30 | completed | S |
| Dostarlimab 50 mg/mL injection, 1000 mg intravenously over 30 minutes every 6 weeks as maintenance, for up to three years | Every 6 weeks | Intravenous route | 2026-06-30 | active | S |
| Levothyroxine 75 mcg oral tablet, one tablet daily before breakfast | One tablet daily before breakfast | Oral route | 2026-06-30 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-30 | Body height | 165 | cm | S |
| 2026-06-30 | Body weight | 72.4 | kg | S |
| 2026-06-30 | Body mass index (BMI) [Ratio] | 26.6 | kg/m2 | S |
| 2026-06-30 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-06-30 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-06-30 | Heart rate | 64 | /min | S |
| 2026-06-30 | Respiratory rate | 16 | /min | S |
| 2026-06-30 | Body temperature | 36.4 | Cel | S |
| 2026-06-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-30 | Hemoglobin [Mass/volume] in Blood | 11.4 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-06-30 | Leukocytes [#/volume] in Blood by Automated count | 4.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-06-30 | Neutrophils [#/volume] in Blood by Automated count | 2.8 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-06-30 | Platelets [#/volume] in Blood by Automated count | 228 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-06-30 | Creatinine [Mass/volume] in Serum or Plasma | 0.84 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-06-30 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 80 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-06-30 | Glucose [Mass/volume] in Serum or Plasma | 90 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-06-30 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-35 U/L | Normal | S |
| 2026-06-30 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 8-35 U/L | Normal | S |
| 2026-06-30 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-06-30 | Thyrotropin [Units/volume] in Serum or Plasma | 11.8 | m[IU]/L | 0.4-4.5 mIU/L | High | S |
| 2026-06-30 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 0.7 | ng/dL | 0.8-1.8 ng/dL | Low | S |
| 2026-06-30 | Cortisol [Mass/volume] in Serum or Plasma | 13.1 | ug/dL | Morning sample, drawn before 9 a.m. | Normal | S |
| 2026-06-30 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S |
Vital signs recorded on 2026-06-30; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well but tired; weight 72.4 kg; blood pressure 122/78, pulse 64, temperature 36.4 °C |
| Neck | Thyroid not enlarged or tender |
| Abdomen | Soft, non-tender; no mass |
| Extremities | No leg swelling; calf circumferences unchanged |
| Neurological | Pinprick slightly reduced over the toes only; ankle reflexes present with a slow relaxation phase; steady gait |
| Psychiatric | Alert and engaged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Postmenopausal bleeding for three weeks, about eight years after her last period, in a woman of 60 who takes no hormone therapy: endometrial cancer must be excluded. Office endometrial biopsy taken today, transvaginal ultrasound this week, and gynecologic oncology review booked | resolved | confirmed | N95.0 | S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded by the diagnosis at the gynecologic oncology consultation. |
| Endometrioid adenocarcinoma of the endometrium, FIGO grade 2, mismatch repair deficient (loss of MLH1 and PMS2 staining), p53 wild-type pattern, on office endometrial biopsy, with enlarged right pelvic and para-aortic lymph nodes on CT; surgical staging planned; synthetic modern detail linked to her publicly reported endometrial cancer | active | confirmed | C54.1 | S — Synthetic histology, molecular result and extent; her family gave endometrial cancer as the cause of death (D), and nothing more about it was made public. |
| Metastatic endometrioid carcinoma in the right external iliac sentinel lymph node (9 mm deposit) and a left para-aortic lymph node (14 mm deposit), with the other nodes removed negative: FIGO 2023 stage IIIC2ii | active | confirmed | C77.8 | S — Synthetic nodal disease found at surgical staging. |
| Chemotherapy-induced peripheral neuropathy from paclitaxel: tingling in the toes, grade 1 (sensory only, no effect on daily activities) | active | confirmed | G62.0 | S — Synthetic common effect of paclitaxel. |
| Immune-related primary hypothyroidism from dostarlimab: TSH 11.8 with a low free T4, tiredness and feeling cold (grade 2) | active | confirmed | E03.2 | S — Synthetic immune-related adverse event, among the most common with PD-1 inhibitors. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Response imaging (CT of the chest, abdomen and pelvis) | At the end of combination treatment | Up to date | A week ago: no evidence of disease |
| Laboratory | Blood count with neutrophils and platelets | Before each cycle; at the end of treatment | Completed today | Hemoglobin 11.4 g/dL, white cells 4.9, neutrophils 2.8, platelets 228; recovered |
| Laboratory | Creatinine and estimated kidney function | Before each checkpoint inhibitor dose | Completed today | Creatinine 0.84 mg/dL, eGFR 80 |
| Laboratory | Liver tests (paclitaxel and checkpoint inhibitor) | Baseline and before each checkpoint inhibitor dose | Completed today | ALT 22, AST 24 U/L, bilirubin 0.5 mg/dL |
| Laboratory | TSH and free T4 (immune-related thyroid disease) | Baseline and before each checkpoint inhibitor dose | Completed today | TSH 11.8 mIU/L and free T4 0.7 ng/dL: immune-related hypothyroidism; levothyroxine started |
| Laboratory | Glucose (immune-related diabetes) | Baseline and before each checkpoint inhibitor dose | Completed today | 90 mg/dL |
| Laboratory | Morning cortisol (immune-related adrenal and pituitary disease) | Baseline and before each checkpoint inhibitor dose | Completed today | 13.1 ug/dL, normal; drawn before 9 a.m. under the standing order |
| Laboratory | CA-125 | Only if raised at diagnosis | Not indicated | Normal at diagnosis (28 U/mL) |
| Examination | Peripheral neuropathy: symptoms and examination | At each visit after taxane treatment | Completed today | Grade 1, stable |
| Examination | Lymphedema | Each visit after lymph node surgery | Completed today | No swelling |
| Examination | Immune-related adverse event symptoms (diarrhea, rash, cough, breathlessness, fatigue, headache) | Each visit on a checkpoint inhibitor | Completed today | Tiredness and cold intolerance, explained by hypothyroidism; no diarrhea, rash, cough or headache |
| Examination | Pelvic examination | Every three months for two years | Due | With gynecologic oncology in three months |
| Imaging | Surveillance CT of the chest, abdomen and pelvis | Every six months for three years for stage III disease | Due | Next in six months |
| Medication safety | Levothyroxine: timing and interactions | At the start | Completed today | Take on an empty stomach before breakfast, four hours apart from calcium or iron |
| Survey | Distress and depression screen (PHQ-9) | At diagnosis, each treatment phase, and when symptoms change | Completed today | PHQ-9 4 |
| Self-management | Survivorship care plan | At the end of active treatment | Completed today | Written plan: visit schedule, symptoms of recurrence to report, lymphedema signs, weight and activity, blood pressure, lipid and glucose care, and screening for other cancers |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026); Mirza MR, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer (RUBY). N Engl J Med 2023;388(23):2145-2158 (PMID 36972026) (2023); JEMPERLI (dostarlimab-gxly) injection, prescribing information (2026); Salani R, et al. Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: A Society of Gynecologic Oncology clinical practice statement. Gynecol Oncol 2026;204:109-117 (PMID 41308226) (2026); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (2020); CMID: Clinical Monitoring Intelligence Database, endometrial cancer and hypothyroidism monographs (2026); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Preventive visit in six weeks with TSH and free T4, on the day of the second maintenance dose. Gynecologic oncology examination in three months; CT in six months. Call for vaginal bleeding, pelvic pain, cough, diarrhea, rash or breathlessness. Next scheduled visit 2026-08-11: periodic adult preventive visit. [S]